Healthcare – Navigating a currency headwind

We see more downside risk over the near term (the ASX200 Healthcare index has underperformed the market by 1.8% over the past month), given an estimated 80% of the movement in the ASX200 healthcare index is negatively correlated to the AUD/USD cross, but note any specific impact will be company specific. For USD reporting names, Ansell, Resmed, and CSL, USD weakness has a positive revenue impact, but can be offset by local cost hedge or rest of the world COGS, while mark-to-market translation is negative for the trading price. For AUD reporting stocks, Sirtex, Cochlear, Ramsay, and Sonic Healthcare, USD weakness is a headwind across both transactions, with the impact only moderated where higher price FX hedges are held, as well as translation. While maintaining a cautious stance to protect against downside risk, we would also be opportunistic as the FX impacts wane and look to position in good quality names underpinned by strong fundamentals, including Healthscope, CSL, and Ramsay.


2 topics

Scott Power
Senior Analyst
Morgans

Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.